HLB bioStep Co.,Ltd.

278650KOSDAQResearch and development

HLB bioStep Co.,Ltd. (278650, KOSDAQ) reported KRW 74bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202353-1-0172104Consolidated
202458-13-10168117Consolidated
202574-9-20156101Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-2.4%-0.1%60.3%-0.1%
2024-22.3%-16.7%69.4%-8.3%
2025-11.6%-27.4%64.9%-20.1%

Revenue moved 40.2% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 40bn
Close priceKRW 2,300
Listed shares17,432,396
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)150
Women57 (38%)
Average tenure4.4 years
Annual pay, menKRW 69,608,484
Annual pay, womenKRW 48,849,754
Pay ratio, women to men70.2%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →